Insmed (NASDAQ:INSM) COO Roger Adsett Sells 239,850 Shares

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. This represents a 70.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Wednesday, June 3rd, Roger Adsett sold 2,370 shares of Insmed stock. The shares were sold at an average price of $102.27, for a total transaction of $242,379.90.

Insmed Stock Down 0.2%

Shares of Insmed stock opened at $132.28 on Thursday. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75. The company has a market capitalization of $28.89 billion, a PE ratio of -32.18 and a beta of 0.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The business has a 50-day moving average of $106.86 and a 200-day moving average of $128.44.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.61. The business had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The company’s revenue was up 296.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.70) earnings per share. As a group, equities analysts forecast that Insmed, Inc. will post -1.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Insmed

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new position in Insmed in the second quarter valued at approximately $139,966,000. S&CO Inc. acquired a new stake in shares of Insmed during the 2nd quarter worth approximately $1,386,000. E. Ohman J or Asset Management AB raised its position in shares of Insmed by 48.7% during the 2nd quarter. E. Ohman J or Asset Management AB now owns 7,789 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 2,550 shares during the period. Handelsbanken Fonder AB lifted its holdings in shares of Insmed by 180.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 189,581 shares of the biopharmaceutical company’s stock worth $20,213,000 after purchasing an additional 122,100 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC bought a new stake in shares of Insmed in the 2nd quarter worth approximately $498,000.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and set a $175.00 target price on shares of Insmed in a research note on Thursday, August 6th. Evercore reaffirmed an “outperform” rating and issued a $170.00 price target on shares of Insmed in a report on Friday, August 7th. Mizuho set a $192.00 price objective on shares of Insmed in a research note on Tuesday, June 16th. Roth Capital reissued a “buy” rating on shares of Insmed in a report on Monday, June 8th. Finally, Guggenheim dropped their target price on shares of Insmed from $207.00 to $205.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Insmed presently has a consensus rating of “Buy” and an average price target of $205.52.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its EPS forecasts across 2026–2030. Its estimates improved to losses of $0.31 per share for Q3 2026 and $0.49 for Q4, while forecasts increased to $1.62 for FY2027, $3.38 for FY2028 and $10.92 for FY2030. The upgrades suggest stronger expectations for Insmed’s commercial growth and eventual profitability.
• Positive Sentiment: Insmed partnered with a patient group on a bronchiectasis study, potentially strengthening patient engagement and the company’s clinical evidence base in a key disease area. Insmed partners patient group on bronchiectasis study
• Neutral Sentiment: The reported short-interest data showed zero shares and a zero-day days-to-cover ratio, indicating no meaningful short-position signal; however, the figures appear unreliable because the reported change was listed as “NaN.”
• Negative Sentiment: COO Roger Adsett sold 239,850 shares for approximately $32.0 million at an average price of $133.27, reducing his holdings by 70.84%. Although insider sales can reflect personal financial planning, the size of the transaction may raise concerns about insider conviction and add near-term selling pressure. Insider trading filing
• Negative Sentiment: JPMorgan reportedly lowered its expectations for Insmed’s stock price, a potentially bearish development that contrasts with HC Wainwright’s more constructive earnings outlook. Details of the revised target were not provided. JPMorgan lowers expectations for Insmed stock price

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.